about
Antibodies to tissue transglutaminase C in type I diabetesFine mapping of diabetes-associated IA-2 specific autoantibodiesIslet cell autoantigen 69 antibodies in IDDMSera from patients with IDDM and healthy individuals have antibodies to ICA69 on western blots but do not immunoprecipitate liquid phase antigenZinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4.Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders.Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes.Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome.Diabetes Antibody Standardization Program: First evaluation of assays for autoantibodies to IA-2βDetection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes.Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus.The core cysteines, (C909) of islet antigen-2 and (C945) of islet antigen-2β, are crucial to autoantibody binding in type 1 diabetes.Influenza A viruses grow in human pancreatic cells and cause pancreatitis and diabetes in an animal model.Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.New trend in non-invasive prenatal diagnosis.Islet Autoantibodies.Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease:BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies.miR-204 is associated with an endocrine phenotype in human pancreatic islets but does not regulate the insulin mRNA through MAFA.Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens.Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2.Radiobinding assay for detecting autoantibodies to single epitopes.Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope.Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice.Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen.Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies.A novel LIPS assay for insulin autoantibodies.Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.Reactivity to N-Terminally Truncated GAD65(96-585) Identifies GAD Autoantibodies That Are More Closely Associated With Diabetes Progression in Relatives of Patients With Type 1 Diabetes.IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens.Beta cell function during rapamycin monotherapy in long-term type 1 diabetes.Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific.Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8.(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
P50
Q28145973-9DFE54DC-B7EA-42A4-9B77-0C5DDF54B700Q28185325-301D16A3-EA7C-4B27-A208-E5D19CD31F75Q28288323-E599A5CB-B4A8-4880-A796-06AABE2CE65EQ28306502-477AB1FC-0640-4260-B89F-E10A96B72FDCQ33556707-18374643-9F98-45CF-9AFB-54D8DA04C98EQ34185195-9DBFA19F-5E9E-43D5-8C6A-4D403D92328DQ34517265-999E968A-92DA-4AC4-98B6-63496788648BQ35046614-1B65F192-8D56-4DB1-A08A-13C168A71B88Q35408291-CC0E93C6-EFBD-4A9A-ABB9-450A78D883A6Q35973888-DE88A7BE-99BE-421B-82A0-EE91B57A09BDQ36318504-763D5E26-3CDF-4FF8-BBE6-31985ACCC8BBQ36477325-764E7710-BE52-4D77-9D36-408D43098635Q36506875-36314CDD-1E64-4CFA-91E8-3015A6F230A7Q36796037-0ED704D9-2C72-49B0-8C23-68815E1028FAQ37216267-8596809A-F132-4801-A067-7359809C6895Q37620361-D18BD6C1-2474-4DF6-BF59-99A386EFDDCFQ37720977-D48FDAE9-9151-4C87-AE06-F8B76E21C0F8Q38301353-90B49167-FE15-4F59-A755-93F6FFD15BF5Q38817211-9F9171BB-7EE8-4E0C-A2A9-E68E774D2334Q39908057-ADEAF436-FFFE-44BD-9E8E-B530BA0CA174Q40180256-ECEEE984-CC37-4DEC-8C08-B30B8F0BF23DQ41854466-2AEEF573-E79F-4D52-8295-78AD45236579Q42630537-AC3E5741-04BB-418C-B718-137D0C7DEBEDQ43950710-EC6B186E-61C5-40A0-9534-3C857D7DD1A6Q46574448-4454FCE0-7BD2-4935-B9DF-6DC2CBDBE989Q46577299-2EEE885B-5D37-442A-9706-C16643CDBDAEQ46964354-502BFC3C-1BB3-4E7B-83F6-68320487FDF7Q47376541-ABA7813D-1684-4B3E-BEA6-9B2D12FCCB4EQ47745073-6D042E33-81D1-4FD3-9796-3D31D90873AAQ48060130-B40EE1C5-7E3D-4D4B-B097-35D06FF8C83CQ48069021-899D236F-0824-439C-87C2-FF8C53C51A70Q48300084-BDCC2D8F-FD8E-45FE-A348-3387968AB6C8Q48489811-4A8A8CB3-BE46-4338-B295-B7A35CAACF5DQ49055874-38F1DE00-F341-4AED-A869-088631C45A91Q50158841-310A7E55-418E-428E-B6ED-DA5255ED6D40Q51387648-76BB712F-C254-4873-A89A-C04B202E88E9Q52761779-DACAF102-E68E-45B7-859F-FC00B430B901Q53144369-49C48522-AA08-4386-8142-D78762F1450FQ53314142-0157CA11-917D-4C3C-9C1A-3CDD96A337A5Q54283187-BDABD9F2-4331-4B0F-B426-518909A1BBB8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vito Lampasona
@ast
Vito Lampasona
@en
Vito Lampasona
@es
Vito Lampasona
@nl
Vito Lampasona
@sl
type
label
Vito Lampasona
@ast
Vito Lampasona
@en
Vito Lampasona
@es
Vito Lampasona
@nl
Vito Lampasona
@sl
prefLabel
Vito Lampasona
@ast
Vito Lampasona
@en
Vito Lampasona
@es
Vito Lampasona
@nl
Vito Lampasona
@sl
P106
P1153
7003540130
P21
P31
P3835
vito-lampasona
P496
0000-0001-5162-8445